Technology | May 15, 2015

Application highlights evidence-based treatment options at the point of care

McKesson Specialty Health, Guideline Explorer, cancer, iPad, Clear Value Plus

May 15, 2015 — McKesson Specialty Health announced the availability of Clear Value Plus – Guideline Explorer to iPad users. The Guideline Explorer app is a mobile reference tool that gives users access to evidence-based cancer protocols based on patient attributes.

Available for download on the Apple App Store at no cost, the Guideline Explorer app provides users with an easy-to-use interface for exploring patient-specific treatment options based on the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) and Value Pathways powered by NCCN. Current Clear Value Plus users can access the complete range of evidence-based treatment options and see all treatment choices that are highlighted as part of the Value Pathways powered by NCCN. New iPad users can navigate NCCN Content and explore chemotherapy regimens based on specific patient characteristics and quickly view up-to-date chemotherapy options, as well as known side effect profiles.

The new iPad tool is an extension of McKesson Specialty Health’s Clear Value Plus, a quality support tool for oncologists that highlights evidence-based treatment options at the point of care. The software brings to life Value Pathways powered by NCCN and NCCN Guidelines within the clinical workflow—offering evidence-based protocols at the point of care with the patient. In addition, Clear Value Plus is compatible with multiple provider systems and provides integrated financial information, real-time reporting and benchmarking to demonstrate the value of delivering evidence-based care.

For more information: www.mckessonspecialtyhealth.com


Related Content

News | Artificial Intelligence

Sept. 13, 2024 — Bayer Calantic Digital Solutions has announced the availability of a new eBook that addresses how ...

Time September 12, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Artificial Intelligence

July 22, 2024 — Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class ...

Time July 22, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
Subscribe Now